An AMPK activator as a therapeutic option for congenital nephrogenic diabetes insipidus

Nephrogenic diabetes insipidus (NDI) patients produce large amounts of dilute urine. NDI can be congenital, resulting from mutations in the type-2 vasopressin receptor (V2R), or acquired, resulting from medications such as lithium. There are no effective treatment options for NDI. Activation of PKA...

Descripción completa

Detalles Bibliográficos
Autores principales: Klein, Janet D., Khanna, Ish, Pillarisetti, Ram, Hagan, Rachael A., LaRocque, Lauren M., Rodriguez, Eva L., Sands, Jeff M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119225/
https://www.ncbi.nlm.nih.gov/pubmed/33724959
http://dx.doi.org/10.1172/jci.insight.146419

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119225/
https://www.ncbi.nlm.nih.gov/pubmed/33724959
http://dx.doi.org/10.1172/jci.insight.146419

Ejemplares similares